Chemomab TherapeuticsCMMB
Market Cap: 18.1M
About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Employees: 20
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
45% more capital invested
Capital invested by funds: $1.43M [Q4 2023] → $2.07M (+$639K) [Q1 2024]
0.34% less ownership
Funds ownership: 1.27% [Q4 2023] → 0.94% (-0.34%) [Q1 2024]
13% less funds holding
Funds holding: 16 [Q4 2023] → 14 (-2) [Q1 2024]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
Maxim Group Michael Okunewitch | 215%upside $4 | Buy Initiated | 13 May 2024 |
Oppenheimer Jeff Jones | 372%upside $6 | Outperform Upgraded | 6 May 2024 |
Financial journalist opinion
Based on 4 articles about CMMB published over the past 30 days